TSR-042 (dostarlimab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TSR-042 (dostarlimab), covering 2026-01-06 to 2026-01-06. Get the full timeline:
Most recent: Clinical Trial Update: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer [Phase 1]